What is it?
Prescription redox drug, not an ordinary supplement
1Methylene Blue is methylthioninium chloride, a redox-active thiazine dye and U.S. prescription IV medicine whose label has an indication for acquired methemoglobinemia. Online nootropic drops and powders are not equivalent to labeled injectable medicine.
The cognition signal is small and insufficient for self-use
3A randomized, double-blind fMRI trial enrolled 26 healthy adults and compared a single oral methylene-blue administration with placebo. It reported task-related brain-signal changes and a memory-retrieval finding, but was small, acute, and not a consumer safety or use study.
Alzheimer research does not validate supplement marketing
5Leuco-methylthioninium and hydromethylthionine studies are clinical drug-development programs in Alzheimer populations. They do not validate consumer claims about cognitive decline or healthy cognition.
Names, aliases and forms
Mechanisms of action
Mitochondrial/redox mechanisms cut both ways
6Methylene Blue can participate in redox cycling and has mitochondrial and nitric-oxide/cGMP-related mechanism discussions. Mechanistic plausibility is not safety: the same drug-like activity is part of why dose, product grade, route, and medication context matter.
Potential effects and evidence map
Methylene Blue has a U.S.-labeled IV indication for acquired methemoglobinemia and mechanistic relevance to mitochondrial/redox biology. The nootropic evidence is much thinner: a 26-person randomized fMRI study reported neural and task-related findings after low-dose oral administration. That finding does not establish unsupervised nootropic use. Safety dominates this profile: the U.S. label carries a boxed warning for serotonin syndrome with serotonergic drugs and opioids and has G6PD, pregnancy, hemolysis, renal/hepatic, and route-specific precautions.
A small randomized fMRI study reported attention-related neural/task effects, but this is not enough to establish unsupervised nootropic self-use.
A small human study suggests short-term memory-related effects, but replication and safety context are insufficient for nootropic recommendations.
Methylene Blue is not an established wakefulness, stimulant, or productivity supplement.
Methylthioninium derivatives have Alzheimer and tau-aggregation research context, but this does not validate consumer brain-health claims.
No reliable human mood or wellbeing benefit is established for Methylene Blue as a consumer nootropic.
Dose/listing context
The 1 mg/kg IV regimen in the U.S. prescription label applies to its labeled clinical indication and care setting. It is not an oral nootropic dose and it does not apply to drops, aquarium products, laboratory dyes, or compounded products.
Safety, side effects and risk profile
The U.S. prescription label carries its highest-level warning against combining methylene blue with serotonergic drugs or opioids because serotonin syndrome can be serious or fatal.
In the United States, methylene blue injection is a prescription drug for acquired methemoglobinemia, not an FDA-approved nootropic supplement.
DailyMed includes renal and hepatic impairment cautions and reports hemolysis/hyperbilirubinemia concerns, especially in vulnerable patients.
The U.S. label says methylene blue may cause fetal harm and directs interruption of breastfeeding for up to 8 days after labeled clinical use.
Adverse effects can include pain, headache, dizziness, nausea, vomiting, confusion, sweating, hypertension, and discoloration of urine or skin.
Consumer products vary by salt form, concentration, purity, route, contaminants, and whether they are pharmaceutical, laboratory, aquarium, or compounded preparations.
The label discusses G6PD deficiency, hemolysis, hyperbilirubinemia, renal impairment, hepatic impairment, and interference with pulse oximetry. These are not normal supplement caveats; they require medical context.
The U.S. prescription label says methylene blue may cause fetal harm and directs interruption of breastfeeding for up to 8 days after labeled clinical use. These risks make casual nootropic use inappropriate in pregnancy or lactation.
Interactions and cautions
The U.S. prescription label warns that methylene blue can cause serious or fatal serotonin syndrome with serotonergic drugs and opioids. It specifically names SSRIs, SNRIs, MAOIs, opioids, bupropion, buspirone, clomipramine, mirtazapine, linezolid, and dextromethorphan.
Legal and regulatory status
In the United States, PROVAYBLUE methylene blue injection is a prescription drug label under an NDA and specifies an IV indication for acquired methemoglobinemia. This does not establish approval for nootropic, anti-aging, mood, mitochondrial, Alzheimer, or wellness claims or establish that nonpharmaceutical products are safe to ingest.
Practical buying and quality notes
- Avoid aquarium, textile, laboratory, reagent, or unclear-grade methylene blue for ingestion. Labels should not be trusted unless they clearly identify pharmaceutical-grade source, concentration, contaminants, batch testing, route, and medical-use context.1
- Do not combine methylene blue with serotonergic medicines, opioids, or dextromethorphan without a prescriber or pharmacist who can assess the interaction risk. Its prescription label carries a boxed warning for this issue.1
FAQ
Is Methylene Blue a nootropic?
3It has a small human attention/memory signal, but it is better regarded as a drug-like redox compound with critical safety constraints, not a routine nootropic supplement.
Is there a consumer nootropic dose?
1No validated consumer nootropic dose is established. The U.S. label describes IV administration for its specified clinical indication, not an oral nootropic regimen or a conversion for drops, aquarium products, laboratory dyes, or compounded products.
Who should avoid unsupervised Methylene Blue?
1Anyone using SSRIs, SNRIs, MAOIs, opioids, serotonergic supplements, dextromethorphan, tramadol, linezolid, or complex medications; anyone with G6PD deficiency, pregnancy, breastfeeding, kidney/liver disease, or unclear product grade; and anyone considering nonpharmaceutical products.
References
- DailyMed. PROVAYBLUE (methylene blue) injection prescribing information, updated May 2025. Accessed 2026-08-21.
- PubChem. Methylene Blue, CID 6099. Accessed 2026-06-30.
- Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. 2016;281(2):516-526.
- Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) Monotherapy for Treatment of Mild Alzheimer's Disease. Journal of Alzheimer's Disease. 2018;61(1):435-457.
- Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3 Trial. Journal of Prevention of Alzheimer's Disease. 2022;9(1):111-122.
- Methylene blue and Alzheimer's disease. Biochemical Pharmacology. 2009;78(8):927-932.